Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.47 |
| ▸ | HTR2B | P41595 | 14/20 | 0.47 |
| ▸ | HTR2A | P28223 | 9/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127628 | 0.70 | DYRK1A (0.43) | — | |
| SCHEMBL7126996 | 0.70 | HTR2C (0.47) | HTR2CHTR2BMTORPIK3CDPIK3CA | |
| SCHEMBL7126557 | 0.70 | HTR2C (0.51) | HTR2CHTR2BMTORPIK3CDPIK3CA | |
| SCHEMBL7125103 | 0.69 | HTR2C (0.45) | HTR2CHTR2BHTR2AMTORNPC1 | |
| SCHEMBL14874767 | 0.69 | HTR2C (0.53) | HTR2CHTR2BHTR2A | |
| SCHEMBL7127603 | 0.68 | HTR2C (0.57) | HTR2CHTR2B | |
| SCHEMBL6312109 | 0.68 | HTR2C (0.77) | HTR2CHTR2BHTR2AMTORNPC1 | |
| SCHEMBL13780834 | 0.67 | DYRK1A (0.66) | HTR2CHTR2BHTR2ANPC1RAB9A | |
| SCHEMBL7126866 | 0.66 | EGFR (0.45) | — | |
| SCHEMBL7124200 | 0.66 | KDM4E (0.41) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | HTR2C 234/4885HTR2B 419/4885HTR2A 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.